Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of the agent for reducing the expression or activity of lc-3b in the preparation of a drug that enhances lycorine's anti-liver cancer activity

A technology for anti-liver cancer and lycorine, which can be used in drug combinations, anti-tumor drugs, organic active ingredients, etc., and can solve problems such as unclear molecular mechanisms

Active Publication Date: 2020-09-08
TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, its precise molecular mechanism is still unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of the agent for reducing the expression or activity of lc-3b in the preparation of a drug that enhances lycorine's anti-liver cancer activity
  • Application of the agent for reducing the expression or activity of lc-3b in the preparation of a drug that enhances lycorine's anti-liver cancer activity
  • Application of the agent for reducing the expression or activity of lc-3b in the preparation of a drug that enhances lycorine's anti-liver cancer activity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] Example 1. Autophagy inhibitors enhance the anti-liver cancer activity of lycorine (the combination of autophagy inhibitors and lycorine enhances the apoptosis of liver cancer cells)

[0064] 1. Lycorine inhibits the growth of hepatocellular carcinoma

[0065] The cell viability was determined by MTT assay, and the growth inhibitory effect of lycorine on three typical human hepatocellular carcinoma cell lines (HepG2, SMMC-7721, HuH-7) and the non-tumorigenic human liver cell line (ChangLiver ). HepG2, SMMC-7721, HuH-7 and Chang Liver were cultured for 48 hours with the medium containing lycorine at 0, 10, 20, 30, 40 and 50 μM respectively, and the cell viability was determined by MTT method. The results showed that 10, 20 , 30, 40, and 50 μM lycorine were treated for 48 hours, and the viability of liver cancer cells was significantly reduced. At the same time, lycorine did not affect the cell viability of normal liver cells Chang Liver at the same dose ( figure 1 Midd...

Embodiment 2

[0084] Example 2. siRNA targeting LC-3B enhances the anti-liver cancer activity of lycorine, and siRNA targeting LC-3B and lycorine have a synergistic effect in anti-liver cancer

[0085] NCBI Reference Sequence of Human Microtubule-Associated Protein 1 Light Chain 3β (Homo sapiens microtubule associated protein 1 light chain 3beta, MAP1LC3B, LC-3B for short) gene: NM_022818.4 (Update Date: 10-JUL-2017).

[0086] This experiment selects random double-stranded RNA as negative control siRNA, and the name of this random double-stranded RNA is siNC, and the nucleotide sequence from the 5' end to the 3' end of a strand of siNC is (5'-uucuccgaacgugucacguTT-3'), The nucleotide sequence from the 3' end to the 5' end of the other chain of siNC is (3'-TTaagaggcuugcacagugca-5').

[0087] In this experiment, two siRNAs targeting human LC-3B were selected, named LC-3B-1 and LC-3B-2 respectively, the nucleotide sequence from the 5' end to the 3' end of a chain of LC-3B-1 For (5'-gcucuucuag...

Embodiment 3

[0099] Example 3, Akt inhibitor enhances the anti-liver cancer activity of lycorine (the combination of Akt inhibitor and lycorine enhances the apoptosis of liver cancer cells)

[0100] 1. Lycorine promotes apoptosis and autophagy of liver cancer cells through TCRP1 / Akt / mTOR signaling pathway

[0101] The experiment was carried out with reference to the corresponding experimental method in Example 1.

[0102] Tongue cancer resistance-associated protein 1 (TCRP1) was reported to promote tumorigenesis in radiation-resistant oral squamous cell carcinoma by selectively activating PI3K / Akt and NF-KB pathways. Such as Figure 4 As shown in middle a, lycorine treatment significantly reduced the expression of TCRP1 protein level in hepatoma cells. However, lycorine treatment did not significantly alter the mRNA levels of TCRP1 ( Figure 4 In b), this indicates that the TCRP1 protein is largely transferred through proteasomal degradation. Subsequently, treatment with MG-132 (a prot...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of a reagent for reducing the expression or activity of LC-3B in the preparation of a drug that enhances lycorine's anti-liver cancer activity. The present invention specifically provides the application of a reagent for reducing the expression or activity of LC-3B in the preparation of products that enhance lycorine's anti-hepatic cancer activity or anti-hepatoma cell activity. Experiments have shown that the apoptosis rate of liver cancer cells treated with the combination of the agent that reduces the expression or activity of LC-3B and lycorine is higher than the apoptosis rate of liver cancer cells that is administered alone with the agent that reduces the expression or activity of LC-3B and that of lycorine alone. The sum of the apoptosis rate of liver cancer cells was even higher. It shows that the agent that reduces the expression or activity of LC-3B and lycorine have a synergistic effect on anti-liver cancer, and the agent that reduces the expression or activity of LC-3B enhances the anti-hepatoma activity of lycorine.

Description

technical field [0001] The present invention relates to the application of the reagent for reducing the expression or activity of LC-3B, in particular to the application of the reagent for reducing the expression or activity of LC-3B in the preparation of a drug for enhancing the anti-liver cancer activity of lycorine. Background technique [0002] Hepatocellular carcinoma (HCC) is one of the most common aggressive tumors worldwide. Liver cancer is a highly lethal tumor with median survival remaining below 1 year after diagnosis. HCC is a heterogeneous disease originating from chronic liver diseases such as chronic inflammation and cirrhosis. So far, the treatment strategies for liver cancer mainly include resection, transplantation, local ablation and chemotherapy. Because the early symptoms of liver cancer are not obvious, most patients with liver cancer are diagnosed at advanced stage and lose the chance of surgery. Most patients who have undergone surgery in time will ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/06A61K31/7105A61K48/00A61K31/437A61P35/00
CPCA61K45/06A61K31/437A61K31/7105A61P35/00A61K2300/00
Inventor 于海洋邱玉玲王涛刘二伟高秀梅陈璐吴红华尹双双
Owner TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com